학술논문
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Document Type
Article
Author
Source
In Annals of Oncology November 2020 31(11):1526-1535
Subject
Language
ISSN
0923-7534